| Health / Medical Topics |
MVA-EBNA1/LMP2 Vaccine
A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the gene for the CD4 epitope-rich C-terminal domain of the Epstein Barr Virus (EBV) antigen EBNA1 and fused to the full-length of the EBV-associated antigen latent membrane protein 2 (LMP2), with potential immunostimulatory and antineoplastic activities. Upon administration, MVA EBNA1/LMP2 vaccine may elicit a cytotoxic T-cell immune response against cancer cells expressing EBNA1 and LMP2. Multi-antigen vaccine therapy may be more efficacious than single-antigen therapy vaccine therapy. EBNA1, a sequence-specific DNA binding protein, plays an important role in EBV episomal genome maintenance and gene transactivation. (NCI Thesaurus)
YOU MAY ALSO LIKE
An autosomal recessive hereditary neoplastic syndrome caused by mutations in the MUTYH gene on chromosome 1p34.1. It is characterized by the…
Human MUTYH allele is located within 1p34.3-p32.1 and is approximately 92 kb in length. This allele, which encodes A/G-specific adenine DNA glycosylase…
A molecular genetic abnormality that refers to the mutation of the MUTYH gene on chromosome 1p34.1.
This gene plays a role in the repair of oxidative DNA damage.
Characterized or delimited reciprocally, in a mutual or shared manner.
Expresses the extent to which the observed frequency of co-occurrence differs from that expected under the null hypothesis.
